DBV Technologies Presents Positive VITESSE Study Data at EAACI Congress 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: Newsfilter
- VITESSE Study Results: The Phase 3 VITESSE study demonstrated that the VIASKIN® Peanut Patch showed significant efficacy in children aged 4 to 7 with peanut allergies, with a response rate of 46.6% at 12 months compared to 14.9% in the placebo group among 654 participants, indicating potential clinical value in treating children with concomitant atopic conditions like asthma.
- Clinical Trial Design: DBV Technologies will present the design of its newly initiated THRIVE Phase 2 study at the EAACI Congress, which aims to assess the safety and efficacy of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, enrolling approximately 250 participants, with results expected to inform future immunotherapy protocols.
- Comorbidity Prevalence: The VITESSE study revealed that 35.8% of participants had asthma, 56.6% had additional food allergies, and 61.8% had atopic dermatitis, highlighting the high prevalence of multiple allergic comorbidities in children with peanut allergies and the need for targeted treatment options.
- Potential for Early Intervention: DBV's Chief Medical Officer emphasized that the successful application of the VIASKIN® Peanut Patch could provide new treatment options for early intervention, helping to shape long-term allergy management strategies and further enhancing the company's market position in the food allergy sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.280
Low
40.00
Averages
46.40
High
51.00
Current: 16.280
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies Presents Positive VITESSE Study Data at EAACI Congress 2026
- VITESSE Study Results: The Phase 3 VITESSE study demonstrated that the VIASKIN® Peanut Patch showed significant efficacy in children aged 4 to 7 with peanut allergies, with a response rate of 46.6% at 12 months compared to 14.9% in the placebo group among 654 participants, indicating potential clinical value in treating children with concomitant atopic conditions like asthma.
- Clinical Trial Design: DBV Technologies will present the design of its newly initiated THRIVE Phase 2 study at the EAACI Congress, which aims to assess the safety and efficacy of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, enrolling approximately 250 participants, with results expected to inform future immunotherapy protocols.
- Comorbidity Prevalence: The VITESSE study revealed that 35.8% of participants had asthma, 56.6% had additional food allergies, and 61.8% had atopic dermatitis, highlighting the high prevalence of multiple allergic comorbidities in children with peanut allergies and the need for targeted treatment options.
- Potential for Early Intervention: DBV's Chief Medical Officer emphasized that the successful application of the VIASKIN® Peanut Patch could provide new treatment options for early intervention, helping to shape long-term allergy management strategies and further enhancing the company's market position in the food allergy sector.
See More
DBV Technologies to Participate in Goldman Sachs Global Healthcare Conference
- Goldman Sachs Conference: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing the company's advancements in food allergy treatments, which is expected to attract investor interest.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin, aiming to non-invasively re-educate the immune system to alleviate food allergy symptoms, presenting significant market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials of the VIASKIN Peanut patch for peanut-allergic toddlers and children aged 1 to 7, and successful outcomes could significantly improve the quality of life for millions of children, enhancing the company's leadership position in the biopharmaceutical sector.
- Market Positioning: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its global market strategy and investment appeal.
See More
DBV Technologies Holds 2026 General Meeting with All Resolutions Approved
- General Meeting Outcome: DBV Technologies held its General Meeting on June 3, 2026, in Châtillon, France, where shareholders approved all proposed resolutions, reflecting investor confidence in the company's future direction.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology aimed at treating food allergies through epicutaneous immunotherapy, addressing significant unmet medical needs for millions of patients, which presents substantial market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials for the VIASKIN Peanut Patch targeting food-allergic children aged 1 to 7 years, aiming to enhance patient quality of life through a non-invasive treatment approach.
- Market Positioning: DBV Technologies' ordinary shares are traded on Euronext Paris, while its ADSs are listed on Nasdaq, showcasing its strategic positioning in the global market and attractiveness to investors.
See More
Total Voting Rights and Shares as of May 31, 2026
- Total Shares: As of May 31, 2026, the company has a total of 296,061,497 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing and shareholder confidence.
- Total Voting Rights: The total voting rights on the same date amount to 296,061,497, reflecting the level of shareholder participation in corporate governance, thereby enhancing the company's transparency and decision-making authority for shareholders.
- Net Voting Rights: The net voting rights stand at 295,906,088, accounting for shares without voting rights, indicating a certain level of governance efficiency in the shareholder structure, which helps to build trust in the management.
- Regulatory Compliance: The company has disclosed voting rights and share information in a timely manner in accordance with the regulations of the Autorité des Marchés Financiers, demonstrating its commitment to compliance and transparency, which can enhance investor confidence.
See More
DBV Technologies Launches THRIVE Phase 2 Study for VIASKIN® Peanut Patch
- Study Initiation: DBV Technologies has screened its first participant in the THRIVE Phase 2 study, aimed at evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, marking a significant advancement in peanut allergy treatment.
- Clinical Trial Design: This single-arm, open-label study will have participants wear the VIASKIN® Peanut Patch daily for 36 months while maintaining a peanut-free diet, followed by a peanut food challenge at 36 months to assess its impact on peanut tolerance.
- Potential for Early Intervention: Principal investigator Dr. Douglas Mack emphasizes that early interventions may influence allergy management and long-term outcomes, and the success of the THRIVE study could provide critical insights into peanut allergy treatment strategies.
- Company Vision: DBV Technologies CEO Daniel Tassé states that this study represents an important step in the company's mission to transform the lives of children with peanut allergies, and if successful, it will lay the groundwork for future treatment options.
See More
DBV Technologies to Hold 2026 Shareholders' Meeting
- Meeting Announcement: DBV Technologies will hold its Combined General Meeting on June 3, 2026, at 10:00 a.m. CEST at its headquarters in Châtillon, France, with notices published on April 29 and today to ensure shareholders are informed.
- Information Access Procedures: Shareholders can access preparatory documents for the meeting on the company's website, and those wishing to receive documents via email must request them by midnight Paris time on May 29, 2026, promoting transparency and shareholder engagement.
- Webcast Arrangements: The General Meeting will be webcast live on the company's website, with updates provided if technical issues arise, ensuring shareholders can access the meeting content in real-time.
- Company Background: DBV Technologies is a late-stage biopharmaceutical firm focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology, aiming to improve the quality of life for millions suffering from food allergies.
See More
DBV Technologies Presents Positive VITESSE Study Data at EAACI Congress 2026
- VITESSE Study Results: The Phase 3 VITESSE study demonstrated that the VIASKIN® Peanut Patch showed significant efficacy in children aged 4 to 7 with peanut allergies, with a response rate of 46.6% at 12 months compared to 14.9% in the placebo group among 654 participants, indicating potential clinical value in treating children with concomitant atopic conditions like asthma.
- Clinical Trial Design: DBV Technologies will present the design of its newly initiated THRIVE Phase 2 study at the EAACI Congress, which aims to assess the safety and efficacy of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, enrolling approximately 250 participants, with results expected to inform future immunotherapy protocols.
- Comorbidity Prevalence: The VITESSE study revealed that 35.8% of participants had asthma, 56.6% had additional food allergies, and 61.8% had atopic dermatitis, highlighting the high prevalence of multiple allergic comorbidities in children with peanut allergies and the need for targeted treatment options.
- Potential for Early Intervention: DBV's Chief Medical Officer emphasized that the successful application of the VIASKIN® Peanut Patch could provide new treatment options for early intervention, helping to shape long-term allergy management strategies and further enhancing the company's market position in the food allergy sector.
See More
DBV Technologies to Participate in Goldman Sachs Global Healthcare Conference
- Goldman Sachs Conference: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, showcasing the company's advancements in food allergy treatments, which is expected to attract investor interest.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin, aiming to non-invasively re-educate the immune system to alleviate food allergy symptoms, presenting significant market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials of the VIASKIN Peanut patch for peanut-allergic toddlers and children aged 1 to 7, and successful outcomes could significantly improve the quality of life for millions of children, enhancing the company's leadership position in the biopharmaceutical sector.
- Market Positioning: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its global market strategy and investment appeal.
See More
DBV Technologies Holds 2026 General Meeting with All Resolutions Approved
- General Meeting Outcome: DBV Technologies held its General Meeting on June 3, 2026, in Châtillon, France, where shareholders approved all proposed resolutions, reflecting investor confidence in the company's future direction.
- Technological Innovation: The company focuses on developing its proprietary VIASKIN® patch technology aimed at treating food allergies through epicutaneous immunotherapy, addressing significant unmet medical needs for millions of patients, which presents substantial market potential.
- Clinical Trial Progress: DBV is currently conducting clinical trials for the VIASKIN Peanut Patch targeting food-allergic children aged 1 to 7 years, aiming to enhance patient quality of life through a non-invasive treatment approach.
- Market Positioning: DBV Technologies' ordinary shares are traded on Euronext Paris, while its ADSs are listed on Nasdaq, showcasing its strategic positioning in the global market and attractiveness to investors.
See More
Total Voting Rights and Shares as of May 31, 2026
- Total Shares: As of May 31, 2026, the company has a total of 296,061,497 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing and shareholder confidence.
- Total Voting Rights: The total voting rights on the same date amount to 296,061,497, reflecting the level of shareholder participation in corporate governance, thereby enhancing the company's transparency and decision-making authority for shareholders.
- Net Voting Rights: The net voting rights stand at 295,906,088, accounting for shares without voting rights, indicating a certain level of governance efficiency in the shareholder structure, which helps to build trust in the management.
- Regulatory Compliance: The company has disclosed voting rights and share information in a timely manner in accordance with the regulations of the Autorité des Marchés Financiers, demonstrating its commitment to compliance and transparency, which can enhance investor confidence.
See More
DBV Technologies Launches THRIVE Phase 2 Study for VIASKIN® Peanut Patch
- Study Initiation: DBV Technologies has screened its first participant in the THRIVE Phase 2 study, aimed at evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants aged 6 to 12 months, marking a significant advancement in peanut allergy treatment.
- Clinical Trial Design: This single-arm, open-label study will have participants wear the VIASKIN® Peanut Patch daily for 36 months while maintaining a peanut-free diet, followed by a peanut food challenge at 36 months to assess its impact on peanut tolerance.
- Potential for Early Intervention: Principal investigator Dr. Douglas Mack emphasizes that early interventions may influence allergy management and long-term outcomes, and the success of the THRIVE study could provide critical insights into peanut allergy treatment strategies.
- Company Vision: DBV Technologies CEO Daniel Tassé states that this study represents an important step in the company's mission to transform the lives of children with peanut allergies, and if successful, it will lay the groundwork for future treatment options.
See More
DBV Technologies to Hold 2026 Shareholders' Meeting
- Meeting Announcement: DBV Technologies will hold its Combined General Meeting on June 3, 2026, at 10:00 a.m. CEST at its headquarters in Châtillon, France, with notices published on April 29 and today to ensure shareholders are informed.
- Information Access Procedures: Shareholders can access preparatory documents for the meeting on the company's website, and those wishing to receive documents via email must request them by midnight Paris time on May 29, 2026, promoting transparency and shareholder engagement.
- Webcast Arrangements: The General Meeting will be webcast live on the company's website, with updates provided if technical issues arise, ensuring shareholders can access the meeting content in real-time.
- Company Background: DBV Technologies is a late-stage biopharmaceutical firm focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology, aiming to improve the quality of life for millions suffering from food allergies.
See More
